Signify Premium Insight: RadNet is Full Screen Ahead with AI Acquisitions
Published: February 3, 2022
Many investors are impatient creatures. This impatience often serves them well, allowing them to spot a suitable opportunity and make a tidy return in a relatively short time frame. For the companies they invest in, however, this impatience can force them to alter and adapt their strategies, and ensure they must react to opportunities.
This flexibility is particularly important if a company is running at a loss of around $4-$5m dollars a year, against a figure of just $13m raised from venture capital investors. This is the situation that Aidence and Quantib found themselves in. Both vendors had developed promising AI technology but, with AI adoption in its infancy, commercialising and capitalising on this technology is still something of a challenge.
Read the full insight with a Signify Premium Insights – Medical Imaging subscriptionSign up for a free trial today.
Machine Learning in Medical Imaging ServiceOngoing series of reports, data and insights delivered over the year
Machine Learning in Medical Imaging Service
This Market Intelligence Service provides regular data, insights and analysis on the global market opportunity for AI-based medical image analysis.
Find out more